Townsquare Capital LLC reduced its position in GALAPAGOS NV/S (NASDAQ:GLPG) by 39.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,603 shares of the biotechnology company’s stock after selling 1,064 shares during the quarter. Townsquare Capital LLC’s holdings in GALAPAGOS NV/S were worth $306,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in GLPG. Cormorant Asset Management LP boosted its position in shares of GALAPAGOS NV/S by 0.5% during the second quarter. Cormorant Asset Management LP now owns 99,075 shares of the biotechnology company’s stock valued at $19,484,000 after buying an additional 472 shares during the period. Capital Asset Advisory Services LLC lifted its stake in shares of GALAPAGOS NV/S by 14.0% during the 2nd quarter. Capital Asset Advisory Services LLC now owns 1,994 shares of the biotechnology company’s stock worth $370,000 after acquiring an additional 245 shares during the last quarter. Stifel Financial Corp boosted its holdings in GALAPAGOS NV/S by 2.9% during the 2nd quarter. Stifel Financial Corp now owns 23,790 shares of the biotechnology company’s stock valued at $4,693,000 after acquiring an additional 664 shares during the period. Baird Financial Group Inc. grew its position in GALAPAGOS NV/S by 15.1% in the 2nd quarter. Baird Financial Group Inc. now owns 2,020 shares of the biotechnology company’s stock valued at $418,000 after acquiring an additional 265 shares during the last quarter. Finally, Federated Hermes Inc. increased its stake in GALAPAGOS NV/S by 1.1% in the second quarter. Federated Hermes Inc. now owns 1,421,640 shares of the biotechnology company’s stock worth $280,475,000 after purchasing an additional 15,097 shares during the period. 11.58% of the stock is owned by institutional investors and hedge funds.
GLPG stock traded up $1.80 during trading on Tuesday, reaching $136.75. 804 shares of the company traded hands, compared to its average volume of 156,848. The business has a 50 day simple moving average of $159.99 and a 200 day simple moving average of $191.13. GALAPAGOS NV/S has a 12 month low of $112.00 and a 12 month high of $274.03. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.09 and a current ratio of 9.09. The company has a market capitalization of $8.81 billion, a price-to-earnings ratio of 86.51 and a beta of 0.94.
GALAPAGOS NV/S (NASDAQ:GLPG) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($1.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.88). GALAPAGOS NV/S had a net margin of 8.13% and a return on equity of 8.24%. The company had revenue of $129.53 million during the quarter, compared to analysts’ expectations of $118.41 million. As a group, research analysts forecast that GALAPAGOS NV/S will post -4.87 EPS for the current year.
GLPG has been the subject of a number of recent analyst reports. Stifel Nicolaus reissued a “hold” rating on shares of GALAPAGOS NV/S in a research note on Friday. BidaskClub downgraded shares of GALAPAGOS NV/S from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 9th. Morgan Stanley decreased their price target on shares of GALAPAGOS NV/S from $221.00 to $158.00 and set an “equal weight” rating for the company in a research note on Friday, August 21st. Cantor Fitzgerald lowered their price target on GALAPAGOS NV/S from $192.00 to $134.00 and set a “neutral” rating for the company in a report on Wednesday, August 19th. Finally, UBS Group restated a “neutral” rating on shares of GALAPAGOS NV/S in a report on Monday, May 18th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the company’s stock. GALAPAGOS NV/S has an average rating of “Hold” and a consensus price target of $190.23.
GALAPAGOS NV/S Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Read More: Options Trading
Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GALAPAGOS NV/S (NASDAQ:GLPG).
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.